stockrowMirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
Follow MIRM
Alert me
Mirum Pharmaceuticals, Inc. (MIRM) Return on invested capital
Mirum Pharmaceuticals, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −184.7%, down 178.9 percentage points from fiscal 2025 (−5.74%). Over the past ten years it has ranged from −202.0% (fiscal 2019) to 0.00% (fiscal 2020); the current reading is higher than 75% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −5.74% | 15.87 |
| FY2024 | −21.6% | 3.77 |
| FY2023 | −25.4% | 36.79 |
| FY2022 | −62.2% | 51.32 |
| FY2021 | −113.5% | (113.49) |
| FY2020 | 0.00% | 201.97 |
| FY2019 | −202.0% | (201.97) |
| FY2018 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | 17.7% |
| LGND Ligand Pharmaceuticals Incorporated compare | 1.27% |
| KOD Kodiak Sciences Inc. compare | 0.00% |
| IONS Ionis Pharmaceuticals, Inc. compare | 0.00% |
| IMVT Immunovant, Inc. compare | 0.00% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −9.55% |
| ORKA Oruka Therapeutics, Inc. compare | −40.2% |
| MIRM Mirum Pharmaceuticals, Inc. | −184.7% |
| CGON CG Oncology, Inc. compare | −4,111.6% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on MIRM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement